(Boursier.com) — Oncodesign launches a capital increase with elimination of shareholders’ preferential subscription rights through a public offer for an amount of approximately €3 million, with the establishment of a priority period for the benefit of existing shareholders.
The subscription period for the Public Offering and the Global Placement will be between January 29 and February 7 inclusive with a priority period for shareholders from January 29 to February 2 inclusive.
The firm price is set at 1.32 euros. The company benefits from a guaranteed offer for an amount of approximately 2 ME by historical shareholders and guarantor investors.
This fundraising will be used to ensure the need for additional financing relating to the Company’s priority clinical and preclinical programs over the next 12 months, namely: its OPM-101 program in inflammatory bowel diseases integrating the development allowing the launch of phase 2a, its OPM-102 program in Oncology, and its STarT program in pancreatic cancer, developed in partnership with Servier.
In addition, the company has received notification of financial aid from the European Regional Development Fund (ERDF) under the FEDER-FSE+ Bourgogne Franche-Comté et Massif du Jura 2021-2027 program.
©2024 Boursier.com